1227210-30-1

Basic information

• Product Name: (1-(2-bromoethyl)-3-nitro-1H-pyrazole-5-yl)methanol
• CAS NO: 1227210-30-1
• Molecular Weight: 250.052
• Mol File: 1227210-30-1.mol
• Article Data: 22

Chemical Properties

• CAS DataBase Reference: (1-(2-bromoethyl)-3-nitro-1H-pyrazole-5-yl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (1-(2-bromoethyl)-3-nitro-1H-pyrazole-5-yl)methanol(1227210-30-1)
• EPA Substance Registry System: (1-(2-bromoethyl)-3-nitro-1H-pyrazole-5-yl)methanol(1227210-30-1)

Safety Data

• Hazardous Substances Data: 1227210-30-1(Hazardous Substances Data)

Upstream product

• 106-93-4 ethylene dibromide 
• 181585-93-3 5-nitro-2H-pyrazole-3-carboxylic acid methyl ester 
• 1360057-00-6 methyl 1-(2-bromoethyl)-3-nitro-1H-pyrazole-5-carboxylate 
• 1000895-25-9 (3-nitro-1H-pyrazol-5-yl)methanol 
• 1000895-25-9 (5-nitro-1H-pyrazol-3-yl)methanol 
• 74-95-3 1,1-dibromomethane 

Downstream Products

• 1227210-31-2 1-(2-bromoethyl)-5-(bromomethyl)-3-nitro-1H-pyrazole 
• 1433854-27-3 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(5-(2,2,2-trifluoro-ethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamino)pyridin-2(1H)-one 
• 1346673-34-4 5-cyclopropyl-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine 
• 1333508-99-8 1-(2-amino-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)ethanone 
• 1333508-96-5 2-nitro-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine 
• 1227210-33-4 5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl-amine 
• 1227210-32-3 5-methyl-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine 
• 1209487-56-8 tert-butyl 2-amino-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate 

Relevant articles and documents

BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY

The present invention relates to compounds of formula (I) useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring C, X1, X2, L1, R1, R2, R3, R4, R5, R6, R7, m and n are as defined herein, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.